Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Worldquant Millennium Advisors LLC

Worldquant Millennium Advisors LLC grew its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 20.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 726,004 shares of the medical research company's stock after buying an additional 125,487 shares during the quarter. Worldquant Millennium Advisors LLC owned 0.12% of Edwards Lifesciences worth $53,746,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Vident Advisory LLC grew its stake in shares of Edwards Lifesciences by 2,938.3% during the fourth quarter. Vident Advisory LLC now owns 295,383 shares of the medical research company's stock valued at $21,867,000 after buying an additional 285,661 shares during the last quarter. Triglav Skladi D.O.O. bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $1,485,000. Two Sigma Investments LP grew its stake in shares of Edwards Lifesciences by 67.7% during the fourth quarter. Two Sigma Investments LP now owns 125,032 shares of the medical research company's stock valued at $9,256,000 after buying an additional 50,463 shares during the last quarter. Tidal Investments LLC grew its stake in shares of Edwards Lifesciences by 18.8% during the fourth quarter. Tidal Investments LLC now owns 46,970 shares of the medical research company's stock valued at $3,477,000 after buying an additional 7,438 shares during the last quarter. Finally, Teza Capital Management LLC grew its stake in shares of Edwards Lifesciences by 13.8% during the fourth quarter. Teza Capital Management LLC now owns 90,836 shares of the medical research company's stock valued at $6,725,000 after buying an additional 10,997 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 1.7%

Shares of NYSE EW traded down $1.30 during mid-day trading on Thursday, reaching $74.80. 4,287,182 shares of the company were exchanged, compared to its average volume of 5,134,490. The firm has a 50-day moving average of $72.69 and a 200 day moving average of $71.99. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The stock has a market cap of $43.88 billion, a price-to-earnings ratio of 10.73, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same period last year, the business posted $0.66 earnings per share. The firm's revenue was up 6.2% compared to the same quarter last year. On average, research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Piper Sandler increased their price objective on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 13th. Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Truist Financial lowered their target price on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. Robert W. Baird upped their target price on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a report on Thursday, April 24th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $80.20.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,500 shares of the stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total value of $112,620.00. Following the transaction, the vice president now directly owns 33,496 shares of the company's stock, valued at approximately $2,514,879.68. This represents a 4.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $70.78, for a total value of $796,275.00. Following the completion of the transaction, the chief financial officer now directly owns 30,387 shares in the company, valued at $2,150,791.86. This represents a 27.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 67,692 shares of company stock worth $4,822,074. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.